search

All clinical trials

Results 460331-460340 of 470744

Expanded Access Protocol for Subjects With Relapsed or Refractory Advanced Solid Tumors Receiving...

Solid Tumor Metastatic Cancer Advanced Cancer

This EAP was designed to provide TJ210001 to the remaining subjects with relapsed or refractory solid tumors who were enrolled on the parent study, TJ210001STM101 (NCT04678921), and plan to continue with treatment.

No longer available11 enrollment criteria

89Zr-DFO-girentuximab Expanded Access Program (EAP)

Clear Cell Renal Cell Carcinoma

The purpose of this Expanded Access Program (EAP) is to enable the use of 89Zr-DFO-girentuximab with positron emission tomography/computed tomography (PET/CT) imaging to non-invasively detect carbonic anhydrase 9 (CAIX)-expressing clear cell renal cell carcinoma (ccRCC) in patients with renal masses as determined by conventional imaging.

Available15 enrollment criteria

Expanded Access to Bimatoprost (Durysta)

Open-angle Glaucoma

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Durysta (Bimatoprost) prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Available5 enrollment criteria

The Multi-Center Study of Shear Wave Elastography on Thyroid Nodules

Thyroid Nodules

The incidence rates of thyroid cancers have increased in the past decade. Additionally, up to 68% of people have thyroid nodules. Consequently, a precise evaluation of thyroid nodules is very important and can avoid unnecessary biopsy of benign nodules. Shear wave elastography(SWE), a novel ultrasound-based elastographic method, is a new real-time, quantitative, operator-independent, and reproducible technique. Briefly, shear wave elastography uses a radiation force produced by an ultrasonic beam to stress tissues and ultrafast sonographic tracking techniques to measure the speed of shear waves. Based on the Young modulus formula, tissue elasticity can be derived from the shear wave propagation speed, and a real-time color-coded elastogram can be displayed, showing softer tissue in blue and stiffer tissue in red. There are lots of research confirmed that SWE has a certain value in the diagnosis of thyroid carcinoma. These studies include prospective studies and retrospective studies, but both belong to a single center study. It has not been applied to the study of the multicenter of thyroid disease. The main purpose of the study is to assess the performance of SWE for identification of benign and malignant thyroid nodules and calculate the optimal cutoff value for each parameter in multicenter study; the secondary purpose is to evaluate the application value of SWE for uncertain nodules by FNA.

Available8 enrollment criteria

An Expanded Access Program of Emicizumab in Participants With Hemophilia A With Inhibitors

Hemophilia A

This open-label, multicenter expanded access program (EAP) is designed to provide emicizumab to eligible participants with hemophilia A with factor VIII (FVIII) inhibitors before it is commercially available in the United States for the indication of hemophilia A with FVIII inhibitors. Discontinuation may occur earlier if participant or physician decides to discontinue treatment or the sponsor discontinues emicizumab clinical development.

Approved for marketing15 enrollment criteria

Therasphere for Unresectable Primary or Secondary Liver Neoplasia

Liver CancerLiver Neoplasms1 more

This is not a research study. The purpose is to provide supervised access to TheraSphere® therapy at this institution.

No longer available11 enrollment criteria

Expanded Access to Nivolumab (Opdivo)

Pediatric Cancer

At BMS, we work with physicians/investigators to make investigational products available to patients with life-threatening diseases that have exhausted other treatment options and where there is a reasonable expectation of benefit over risk. When contacted by a treating physician, BMS will consider requests for providing early patient access to Nivolumab in pediatric patients exhibiting a high mutational load.

Approved for marketing6 enrollment criteria

Detecting Recurrent Prostate Cancer With 11C-choline Positron Emission Tomography

Prostate CancerRecurrent Prostate Cancer

The purpose of this study is to use a new imaging drug called 11C-choline that is used with a PET/CT scan to see prostate cancer when it cannot be seen well on other scans, such as bone scans, CT or MRI.

No longer available10 enrollment criteria

Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of...

Multiple Myeloma in RelapseMultiple Myeloma

Participant that has been diagnosed with Relapsed/ Refractory Multiple Myeloma and are currently participating in a clinical trial which is closing. This research study is studying Ulocuplumab as a possible treatment. It's an expanded access from NCT01359657

No longer available3 enrollment criteria

Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast...

Metastatic Breast Cancer

The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.

Approved for marketing20 enrollment criteria
1...460334603446035...47075

Need Help? Contact our team!


We'll reach out to this number within 24 hrs